Yes. 1 FDA-approved labels for Epoetin Alfa carry a boxed warning, and its subject is esas increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access. A boxed warning is the most serious warning the FDA requires on a prescription label. It is applied to the drug and to the situations in which it is used, not to any particular person taking it.
What the warning says
Below is how the Epoetin Alfa warning opens on one specific label, identified underneath it. Only one Epoetin Alfa label carrying a boxed warning is currently in the FDA database, so there is no second version to compare this wording against.
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE Chronic Kidney Disease: In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL [see Warnings and Precautions ( 5.1 )] . No trial has identified a hemoglobin target level, E SA dose, or dosing strategy that does not increase these risks [see Dosage and Administration ( 2.2 )] .
EPOETIN ALFA, Amgen, Inc, label version effective 23 June 2026. Opening of the warning; read the full label on DailyMed.Only one label carries this warning
There is no single official text of a boxed warning: the FDA sets what a warning must cover and each manufacturer writes its own label within that, so most drugs in this section carry several different wordings. Epoetin Alfa is a case where only one label carrying a boxed warning is currently in the FDA database, so the wording quoted above is simply the wording, with nothing to compare it against.
That is usually a sign of a product with a single supplier rather than of any special agreement about the text. If another manufacturer enters, its wording may differ while describing the same hazard.
Epoetin Alfa is dispensed under 1 current FDA labels despite this warning, which is the point worth holding onto: a boxed warning is a disclosure requirement, not a verdict. What a boxed warning does and does not mean sets out the distinction.
Common questions
Does Epoetin Alfa have a black box warning?
Yes. 1 FDA-approved labels for Epoetin Alfa carry a boxed warning, and its subject is esas increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access. A boxed warning is the strongest warning the FDA requires on a prescription label, and it is applied to the drug, not to any individual taking it.
What does the Epoetin Alfa boxed warning say?
The wording is set by each manufacturer within FDA requirements, so it varies. In the version quoted on this page, taken from a label effective 23 June 2026, the warning concerns esas increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access. The full text is linked so the exact version can be read rather than summarised.
Does the Epoetin Alfa boxed warning mean the drug is unsafe or being withdrawn?
No. It means the FDA requires the risk of esas increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access to be communicated prominently so prescribers weigh it explicitly. Epoetin Alfa remains FDA-approved and is dispensed under 1 current labels. A boxed warning is a disclosure requirement, not a judgement that a drug should not be used.
Is this the only version of the Epoetin Alfa warning?
It is the only one currently in the FDA label database. Most drugs have several manufacturers, each writing its own label within the FDA's requirements, which is why their warning text varies. Only one Epoetin Alfa label carrying a boxed warning is published at present, so there is no second wording to compare against.
Should I stop taking Epoetin Alfa because of this warning?
This page does not answer that and cannot. The warning about esas increase the risk of death, myocardial infarction, stroke, venous thromboembolism, thrombosis of vascular access is written for a prescriber deciding whether Epoetin Alfa suits a particular patient, and stopping a prescribed medicine carries its own risks that this page knows nothing about. Raise it with the prescriber or a pharmacist, who can see the whole picture.
Where this page's information comes from
The quotation above is from one Epoetin Alfa label, linked below by its DailyMed set identifier so the exact version can be opened rather than taken on trust. The figure of 1 labels, and the count of 1 distinct wordings among 1 sampled, were computed from the openFDA labelling API on 30 August 2026.
- EPOETIN ALFA prescribing information, Amgen, Inc, effective 23 June 2026.
- openFDA drug labelling API, the source of the label counts and variant counts on this page.
Labels are revised over time. The version linked above is the one this page was written against, and a newer revision may differ. Counts reflect the labels present in openFDA on the retrieval date.